Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obnitix
- Development stage
- Unknown
- Lead developer
- medac
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Obnitix (MC0518, MSC-FFM) is an allogeneic somatic cell therapy consisting of ex-vivo expanded human bone marrow-derived mesenchymal stromal cells (MSCs). Developed by medac in collaboration with Goethe University Frankfurt and the German Red Cross Blood Service Baden-Württemberg-Hessen, Obnitix is manufactured using a standardized process that pools mononuclear bone marrow cells from eight healthy, HLA-disparate donors to minimize batch-to-batch variability and enhance immunomodulatory potency. The therapy exerts its therapeutic effects through immunomodulation and tissue repair, primarily by inhibiting T- and B-lymphocyte proliferation, reducing dendritic cell activation, and stimulating regulatory T cells via soluble mediators (such as TGF-beta, indoleamine 2,3-dioxygenase, and prostaglandin E2) and direct cell-cell contact. Obnitix is primarily developed for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplantation.
- Brand names
- Obnitix
- Other names
- allogeneic bone marrow-derived mesenchymal stromal cellshuman allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expandedMSC-ObnitixMSC-Obtinix
Beyond the preview
Go deeper on Obnitix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Obnitix.